Solara Active Pharma Sciences SOLARA
API maker (ibuprofen among the world's largest, plus anti-infectives and CNS) spun out of the Strides group
Mapped in 1 theme: Pharmaceuticals.
Where Solara Active Pharma Sciences sits in the supply chain
Solara Active Pharma Sciences appears in 1 supply-chain layer in one theme, Pharmaceuticals.
Pharmaceuticals › APIs (active ingredients)
Direct supplierOther companies in this layer
Revenue and profit
| ₹ Cr | FY24 | FY25 | FY26 |
|---|---|---|---|
| Revenue | 1,289 | 1,284 | 1,369 |
| Net profit | −567 | 1 | −7 |
Latest-year revenue ₹1,369 Cr (FY26, company-wide). Wider screens show FY22 onwards.
Strengths
- Large regulated-market API franchise and turnaround plan with CRAMS push
Risks
- Repeated losses (FY24 loss of ₹567 Cr with write-offs) and weak returns
- Ibuprofen price competition from China
Common questions
What does Solara Active Pharma Sciences do?
API maker (ibuprofen among the world's largest, plus anti-infectives and CNS) spun out of the Strides group.
Where does Solara Active Pharma Sciences sit in the supply chain?
Solara Active Pharma Sciences (NSE: SOLARA) is mapped in 1 supply-chain layer: APIs (active ingredients) (Pharmaceuticals).
Who are Solara Active Pharma Sciences' peers?
In the APIs (active ingredients) layer of Pharmaceuticals: Divi's Laboratories, Laurus Labs, Aarti Drugs, Concord Biotech, Granules India, Neuland Laboratories and 2 more.
What is Solara Active Pharma Sciences' market cap and valuation?
As of 30 Oct 2026: market cap ₹3,072 Cr, P/E 64.9x, ROCE 4.9%, ROE −0.1%, dividend yield 0%.